10-Q/APeriod: Q3 FY2012

AGILENT TECHNOLOGIES, INC. Quarterly Report (Amendment) for Q3 Ended Jul 31, 2012

Filed September 7, 2012For Securities:A

Summary

Agilent Technologies, Inc. reported its financial results for the third quarter of fiscal year 2012, ending July 31, 2012. The company demonstrated solid revenue growth, primarily driven by its life sciences and diagnostics segments. This top-line expansion, coupled with effective cost management, led to an increase in profitability and earnings per share compared to the prior year period. Investors should note the continued strength in recurring revenue streams which provide a stable base for future performance. The company's strategic focus on innovation and market expansion in key growth areas appears to be yielding positive results. While the overall performance was robust, it's important for investors to consider the broader economic environment and potential currency headwinds mentioned in the report. Agilent's management expressed confidence in its ongoing strategies and its ability to navigate challenges, reiterating its full-year guidance. The company's investment in research and development and its commitment to operational efficiency are key factors supporting its long-term growth prospects. Investors seeking exposure to the analytical instruments and life sciences sectors will find Agilent's performance in this quarter to be a positive indicator of its market position and execution capabilities.

Financial Highlights

58 data points
Beta

Revenue

$1.72B

51.7% Gross Margin

Net Income

$243.00M

14.1% Net Margin

EPS (Diluted)

$0.69

Total Assets

$9.76B

Cash & Equivalents

$1.92B

Free Cash Flow

$191.00M

Financial Statements
Beta
Revenue$1.72B
Cost of Revenue$833.00M
Gross Profit$890.00M
R&D Expenses$162.00M
SG&A Expenses$458.00M
Operating Expenses$1.45B
Operating Income$270.00M
Interest Expense$24.00M
Net Income$243.00M
EPS (Basic)$0.70
EPS (Diluted)$0.69
Shares Outstanding (Basic)348.00M
Shares Outstanding (Diluted)353.00M

Key Highlights

  • 1Revenue increased year-over-year, driven by strong performance in Life Sciences and Diagnostics segments.
  • 2Profitability improved, with a notable increase in earnings per share (EPS).
  • 3The company maintained a healthy cash flow position, supporting its operational and strategic investments.
  • 4Recurring revenue remains a significant and stable contributor to overall sales.
  • 5Agilent reiterated its full-year financial guidance, signaling management's confidence in sustained performance.
  • 6Strategic acquisitions and R&D investments are contributing to market share gains and product innovation.

Frequently Asked Questions

Revenue growth was primarily driven by strong demand in the Life Sciences and Diagnostics segments, reflecting successful product launches and increased market penetration.

Yes, Agilent reported improved profitability, with a notable increase in earnings per share (EPS) year-over-year, indicating effective cost management and operational efficiencies.

Agilent management reiterated its full-year financial guidance, suggesting they expect continued solid performance and are confident in their ability to achieve their targets despite potential economic uncertainties.

The company is actively investing in research and development to drive product innovation and is pursuing strategic acquisitions to expand its market reach and capabilities, which are key elements of its long-term growth strategy.